Wednesday, May 18, 2022

What is behind the fall of Inovio Pharmaceuticals Inc. (INO) stock?

Inovio Pharmaceuticals Inc.‎ (INO), a biotechnology company that focuses on the discovery, development, and commercialization of precisely designed DNA medicines to treat and protect people from infectious diseases, announced its plan for phase 3 trial of its COVID-19 vaccine candidate, INO-4800. In accordance to the rapid production of various vaccines, the Defense Health Agency (DHA) along with the relevant authorities, will halt providing funds for phase 3 of the INNOVATE trials.  INO stock plummeted adjacent to the news.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


At last check in premarket trading, shares of Inovio Pharmaceuticals Inc. (INO) declined 26.83% at $6.68.The stock of INO decreased 0.33% to complete the last trading session at $9.13. The price range of the company’s shares fluctuated between $8.92 and $9.37. In the past 12 months, the company’s stock has retreated -22.03%, and in the last week, the stock has moved up 1.33%

About INOVIO Trials.


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


INOVIO’s strategic relationships with Advaccine and the International Vaccine Institute is aiming for a global phase 3 trial, established on safety and immunogenicity data generated from the phase 2 studies. INOVIO will continue the evaluation of its vaccine, focusing to protect against mutated variants of covid 19.

INOVIO’s DNA vaccine, better known as, INO-4800 focuses against SARS-CoV-2, which causes covid-19. INOVIO provides a large number of trials and experience in working with coronaviruses and has pioneered to start a Phase 2a trial for INO-4700, which is a vaccine for a coronavirus that causes Middle East Respiratory Syndrome (MERS). The vaccine is administered directly into the cells to cause an immune response and provide resistance.

NO-4800 is the only nucleic-acid based vaccine that can be safely kept at room temperature (37C) for more than 12 months and consists of a shelf life of 5 years. Furthermore, it does not require to be frozen during transport, which is a hefty consideration in regards to public immunization.

INOVIO presently has 15 DNA medicine clinical programs specializing in HPV-associated diseases, cancer, and infectious diseases, focusing especially on MERS and COVID-19 diseases which is being developed under funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense.

Conclusion

An accumulated total of 3,000 patients have been administered with INOVIO investigational DNA medicines in more than 7,000 applications across a range of broad clinical trials, which has increased investor expectations from the company. However, discontinuation of grants from DHA and the relevant authorities has slowed the clinical trials, due to which INO stock plummeted immensely.

Latest news

Highlights from Financial Report for JD Stock

JD.com Inc. (NASDAQ: JD), a Chinese e-commerce expert, released its first-quarter results. The company's growth slowed slightly, but it was still in the double...

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Related news

Highlights from Financial Report for JD Stock

JD.com Inc. (NASDAQ: JD), a Chinese e-commerce expert, released its first-quarter results. The company's growth slowed slightly, but it was still in the double...

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam